<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3783">
  <stage>Registered</stage>
  <submitdate>11/08/2012</submitdate>
  <approvaldate>11/08/2012</approvaldate>
  <nctid>NCT01776567</nctid>
  <trial_identification>
    <studytitle>Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms</studytitle>
    <scientifictitle>Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms.</scientifictitle>
    <utrn />
    <trialacronym>APPOSE</trialacronym>
    <secondaryid>01/12</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary Artery Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Everolimus eluting stents

Active Comparator: Cobalt Chromium Everolimus-eluting stent (Xience Prime) - Cobalt Chromium Everolimus-eluting stent (Xience Prime)

Active Comparator: Platinum Chromium Everolimus-eluting stent (Promus Element) - Platinum Chromium Everolimus-eluting stent (Promus Element)


Treatment: devices: Everolimus eluting stents


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome> Percent incomplete stent apposition using OCT of the CoCr-EES versus the PtCr-EES stent inflated to nominal pressure and following optimal post-dilatation. Stent length (mm) at implantation following nominal pressure and following post-dilatation</outcome>
      <timepoint>Immediately following stent deployment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of uncovered stent struts</outcome>
      <timepoint>6 mths post initial PCI procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean neointimal tissue thickness (microns)</outcome>
      <timepoint>6 months post initial PCI Procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Stent length (mm) measured using OCT</outcome>
      <timepoint>6 months post initial PCI procedure</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Age = 18 years

          2. Symptomatic coronary artery disease including patients with chronic stable angina,
             silent ischemia, and acute coronary syndromes including non-ST elevation myocardial
             infarction

          3. Presence of one or more coronary artery stenosis &gt; 50% in a native coronary artery
             with a reference diameter ranging from 2.25 to 4.25 mm which can be covered with one
             or multiple stents

          4. No limitation to the number of treated lesions or number of vessels according to the
             randomization group

          5. De-novo native coronary disease with complex lesions involving: Bifurcations, chronic
             occlusions &gt; 3 months, lesions &gt; 20mm in length or moderately/heavily calcified
             lesions of any length</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Known intolerance to aspirin, clopidogrel, heparin, cobalt chromium, platinum
             chromium, everolimus, contrast material

          2. Acute ST-segment elevation myocardial infarction

          3. Type A lesion including vessel angulation &lt;45 degrees

          4. Bypass graft

          5. Inability to provide informed consent

          6. Pregnancy

          7. Planned surgery within 12 months of PCI unless dual antiplatelet therapy is maintained
             throughout the peri-surgical period

          8. Left ventricular ejection fraction &lt; 25%

          9. Serum creatinine &gt; 180mmol/L</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2015</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>Concord Repatriation Hospital - Concord</hospital>
    <hospital>The Prince Charles Hospital - Brisbane</hospital>
    <hospital>Northern Hospital - Epping</hospital>
    <hospital>St Vincent's Hospital - Melbourne</hospital>
    <postcode> - Concord</postcode>
    <postcode> - Brisbane</postcode>
    <postcode>3076 - Epping</postcode>
    <postcode>3065 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Northern Hospital, Australia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Abbott Vascular</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the trial is to directly compare the Cobalt Chromium platform
      everolimus-eluting stent, Xience Prime, with the Platinum Chromium platform
      everolimus-eluting stent, Promus Element, in relation to stent scaffolding shape, position
      with the heart blood vessel and extent of tissue coverage (at 6 months) using optical
      coherence tomography.

      Hypotheses:

        1. The alloy composition and strut design of a drug-eluting stent has a direct bearing on
           stent apposition measured using OCT.

        2. Stent design and alloy composition have a direct influence on radial support and
           scaffold shrinkage.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01776567</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Peter Barlis</name>
      <address>Northern Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Peter Barlis, MBBS MPH PHD FESC FRACP</name>
      <address />
      <phone>+61 3 8405 8554</phone>
      <fax />
      <email>pbarlis@unimelb.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>